Publication: Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status
Published in the Journal of Comparative Effectiveness Research, this paper compares the effectiveness of corticosteroids by age and disease progression across patients from a range of Phase 2b and Phase 3 clinical trials
Explore patient demographics from 4 clinical trials
Compare the efficacy results for 2 different corticosteroid treatments on disease progression through measures such as 6-minute walk distance and North Star Ambulatory Assessment scores
Understand the impact of corticosteroid treatment on motor function from baseline to 48 weeks
McDonald CM, Marden JR, Shieh PB, et al. J Comp Eff Res. 2023;12(4):e220190
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at firstname.lastname@example.org. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300173 | January 2024
Sign in or register to access exclusive content on this site